argenex (ARGX) Competitors $843.66 +6.38 (+0.76%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$843.01 -0.65 (-0.08%) As of 10/17/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARGX vs. SNY, GSK, TAK, ONC, INSM, BNTX, TEVA, GMAB, SMMT, and ASNDShould you be buying argenex stock or one of its competitors? The main competitors of argenex include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. argenex vs. Its Competitors Sanofi GSK Takeda Pharmaceutical BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S argenex (NASDAQ:ARGX) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk. Do insiders & institutionals hold more shares of ARGX or SNY? 60.3% of argenex shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media refer more to ARGX or SNY? In the previous week, argenex had 18 more articles in the media than Sanofi. MarketBeat recorded 33 mentions for argenex and 15 mentions for Sanofi. argenex's average media sentiment score of 0.64 beat Sanofi's score of 0.47 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 14 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, ARGX or SNY? Sanofi has higher revenue and earnings than argenex. Sanofi is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratioargenex$3.05B16.91$833.04M$19.5043.26Sanofi$44.46B2.80$6.02B$4.1612.17 Which has more risk and volatility, ARGX or SNY? argenex has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Is ARGX or SNY more profitable? argenex has a net margin of 40.98% compared to Sanofi's net margin of 21.47%. argenex's return on equity of 21.06% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets argenex40.98% 21.06% 18.25% Sanofi 21.47%16.86%9.63% Do analysts recommend ARGX or SNY? argenex presently has a consensus target price of $817.53, suggesting a potential downside of 3.10%. Sanofi has a consensus target price of $62.67, suggesting a potential upside of 23.80%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than argenex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score argenex 0 Sell rating(s) 2 Hold rating(s) 20 Buy rating(s) 2 Strong Buy rating(s) 3.00Sanofi 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00 Summaryargenex beats Sanofi on 11 of the 15 factors compared between the two stocks. Get argenex News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$51.63B$3.44B$6.20B$10.55BDividend YieldN/A2.28%5.70%4.81%P/E Ratio43.2623.1685.7027.13Price / Sales16.91499.34614.88134.09Price / Cash284.0146.9237.1060.81Price / Book9.3210.4112.236.52Net Income$833.04M-$52.77M$3.33B$276.93M7 Day Performance5.87%2.31%1.17%1.93%1 Month Performance14.51%12.59%6.85%2.19%1 Year Performance49.32%11.18%58.93%34.62% argenex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenex3.5941 of 5 stars$843.66+0.8%$817.53-3.1%+49.3%$51.63B$3.05B43.261,599Analyst RevisionGap DownSNYSanofi4.2022 of 5 stars$48.80+1.5%$62.67+28.4%-7.8%$119.83B$44.46B11.7382,878News CoverageUpcoming EarningsGSKGSK1.8482 of 5 stars$43.67+0.3%$37.38-14.4%+14.0%$88.83B$31.63B20.2268,629Dividend CutTAKTakeda Pharmaceutical3.3803 of 5 stars$13.72+0.0%N/A-2.0%$43.64B$4.48T45.7247,455Analyst ForecastONCBeOne Medicines2.9548 of 5 stars$327.03+2.2%$340.30+4.1%N/A$35.84B$3.81B-189.0311,000INSMInsmed2.9303 of 5 stars$163.94+1.0%$149.06-9.1%+122.4%$34.65B$363.71M-28.711,271News CoveragePositive NewsAnalyst ForecastBNTXBioNTech2.6578 of 5 stars$102.30+0.2%$134.32+31.3%-5.9%$24.59B$2.88B-63.946,772Analyst ForecastTEVATeva Pharmaceutical Industries3.5912 of 5 stars$20.02-0.1%$25.57+27.8%+7.7%$22.96B$16.63B-125.0936,830GMABGenmab A/S3.6437 of 5 stars$32.68+2.7%$40.80+24.8%+44.3%$20.98B$3.26B16.422,682Trending NewsAnalyst ForecastShort Interest ↑Analyst RevisionSMMTSummit Therapeutics3.007 of 5 stars$22.93+7.4%$31.29+36.4%-1.0%$17.03B$700K-22.70110News CoverageUpcoming EarningsGap DownASNDAscendis Pharma A/S2.8366 of 5 stars$208.43-0.5%$244.64+17.4%+62.0%$12.86B$393.54M-40.391,017News CoverageAnalyst UpgradeAnalyst RevisionGap Up Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives GMAB Alternatives SMMT Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARGX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
